ライフサイエンスコーパス: hazard ratio

1 tion (0.54 versus 1.25 events/patient-years, hazard ratio 0.43 [95% CI, 0.39-0.47], P<0.0001).

2 y associated with improved overall survival (hazard ratio 0.53, P < 0.001).

3 associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0

4 nd 40.8 months (36-48) in the placebo group (hazard ratio 0.69, 95% CI 0.58-0.82); 8-year landmark ov

5 11-10.78) with bortezomib and dexamethasone (hazard ratio 0.70 [95% CI 0.53-0.93], p=0.0075).

6 2.6 months (10.6-14.4) in the control group (hazard ratio 0.71 [95% CI 0.57-0.88], p=0.0016).

7 tion (1.67 versus 2.28 events/patient-years, hazard ratio 0.73 [95% CI, 0.68-0.78], P<0.0001).

8 11.1) for those assigned placebo (stratified hazard ratio 0.82, 95% CI 0.55-1.23; p=0.33).

9 10.4-15.0) in the chemotherapy group (n=207; hazard ratio 0.89, 95% CI 0.71-1.11; p=0.30).

10 ge the cumulative incidence (subdistribution hazard ratio 0.91, 95% confidence interval [CI] 0.49-1.6

11 currence (280 [9%] POAI; 154 [10%] control), hazard ratio 0.92 (95% CI 0.75-1.12); p=0.40 with the pr

12 significantly increased mortality (adjusted hazard ratio 0.99, 95% confidence interval 0.62-1.58) or

13 Ptrend = 0.001; and for EA, quintile5 vs. 1 hazard ratio = 0.79, 95% confidence interval: 0.64, 0.98

14 ed HNC and EA risk (for HNC, quintile5 vs. 1 hazard ratio = 0.81, 95% confidence interval: 0.71, 0.92

15 ection elimination group (46.7% versus 6.7%, hazard ratio, 0.12, P=0.047).

16 ower in the microstent group (0.6% vs. 3.9%; hazard ratio, 0.156; 95% confidence interval, 0.031-0.77

17 significant in favor of the screening group (hazard ratio, 0.17; 95% CI, .03-.86).

18 with lenalidomide compared with observation (hazard ratio, 0.28; 95% CI, 0.12 to 0.62; P = .002).

19 ntervention period (week 3 through week 14) (hazard ratio, 0.30; 95% CI, 0.22 to 0.42) and was not su

20 icant lower in the ICD group (5% versus 13%, hazard ratio, 0.37 [95% CI, 0.15-0.95]) after 3 years fo

21 5% CI, 0.18-0.81] P=0.012), and circulating (hazard ratio, 0.38 [95% CI, 0.18-0.80] P=0.011) Ang 1-7/

22 usting for covariates, elevated equilibrium (hazard ratio, 0.38 [95% CI, 0.18-0.81] P=0.012), and cir

23 95% CI, 0.44-0.83]) and high fit (tertile 3: hazard ratio, 0.38 [95% CI, 0.24-0.59]) groups, respecti

24 a lower hazard for HHV-6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80).

25 k among participants with large CHIP clones (hazard ratio, 0.46 [95% CI, 0.29-0.73], P<0.001) but not

26 1.6 months for classifier-negative patients (hazard ratio, 0.49; 95% confidence interval, 0.280-0.86;

27 -0.86]) and without CRT (42.5% versus 66.9%, hazard ratio, 0.52 [95% CI, 0.39-0.69]; adjusted P(inter

28 d inverse probability of treatment weighting hazard ratio, 0.525; 95% CI, 0.240-1.145).

29 d inverse probability of treatment weighting hazard ratio, 0.539; 95% CI, 0.224-1.297) and at 60 days

30 y longer OS was observed with HER2 blockade (hazard ratio, 0.58; 95% CI, 0.34 to 0.97).

31 mol/L increase in HDL-C) and iSPAAR cohorts (hazard ratio, 0.60 [95% CI, 0.37-0.98] per 1 mmol/L incr

32 patients with prior CRT (48.6% versus 67.2%, hazard ratio, 0.60 [95% CI, 0.42-0.86]) and without CRT

33 and 62% lower among moderate fit (tertile 2: hazard ratio, 0.61 [95% CI, 0.44-0.83]) and high fit (te

34 0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95% CI, 0.45-0.81]; P=0.0005).

35 reduced percutaneous coronary intervention (hazard ratio, 0.68 [95% CI, 0.59-0.79]; P<0.0001) and co

36 ce, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 t

37 parts to be promoted to associate professor (hazard ratio, 0.76; 95% confidence interval [CI], 0.74 t

38 ecreased sepsis mortality in the UK Biobank (hazard ratio, 0.77 [95% CI, 0.59-1.00] per 1 mmol/L incr

39 years compared with no PCI (31.5% vs 39.1%; hazard ratio, 0.77 [95% CI, 0.63-0.94]).

40 Apo M remained associated with death (hazard ratio, 0.78 [95% CI, 0.69-0.88]; P<0.0001) and th

41 (95% CI, -2.3 to 0.1) death per 1000 women (hazard ratio, 0.78 [CI, 0.63 to 0.95]) (a negative risk

42 ricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-0.94]; P=0.001) in mode

43 diovascular readmission (19.7% versus 22.9%; hazard ratio, 0.85 [95% CI, 0.80-0.89]), and composite o

44 e PSA was inversely related with recurrence (hazard ratio, 0.9 per nanograms per milliliter of PSA; 9

45 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35).

46 r all-cause readmission (40.4% versus 44.1%; hazard ratio, 0.91 [95% CI, 0.88-0.95]), cardiovascular

47 s noninferior to sorafenib (10.2 and 9.2 mo [hazard ratio, 0.91; 95% confidence interval, 0.78-1.05])

48 t [95% CI, -11.3 to 12.3 percentage points]; hazard ratio, 0.93 [CI, 0.67 to 1.30]; P = 0.67).

49 <0.001) but not in individuals without CHIP (hazard ratio, 0.95 [95% CI, 0.89-1.01], P=0.08; P(intera

50 ent and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 t

51 ortality or readmission (56.0% versus 58.4%; hazard ratio, 0.96 [95% CI, 0.93-1.00]).

52 ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]).

53 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85

54 ox proportional hazard models, age (adjusted hazard ratio, 0.98; 95% CI [0.96-0.99]), anoxic brain in

55 no change within minority-serving hospitals (hazard ratio, 0.99; 95% CI, 0.97-1.01).

56 nts (17%), 6 of 13 (46%), and 5 of 12 (42%) (hazard ratios, 0.30 [95% CI, 0.07 to 1.32] and 0.20 [95%

57 ciated with a decreased rate of progression (hazard ratios, 0.45 and 0.64, respectively).

58 s (36%), 14 of 34 (41%), and 13 of 33 (39%) (hazard ratios, 0.73 [95% CI, 0.34 to 1.52] and 0.76 [95%

59 fferences in time to progression (unadjusted hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted haz

60 uction in cardiovascular mortality (adjusted hazard ratio: 0.10; p = 0.025).

61 d reduction in all-cause mortality (adjusted hazard ratio: 0.12; p = 0.001) and a ~10-fold reduction

62 tive for 1-year CV death/rehospitalizations (hazard ratio: 0.39; 95% confidence interval: 0.19 to 0.8

63 with remaining on the waiting list (adjusted hazard ratio: 0.58; 95% confidence interval: 0.36-0.95;

64 eduction only if 1-year LDL-C was <70 mg/dl (hazard ratio: 0.61; 95% confidence interval: 0.40 to 0.9

65 all-cause-mortality (7.6% vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence interval: 0.53 to 0.7

66 ween reporting CVD events and drug efficacy (hazard ratio: 0.68 vs. 0.67; p = 0.22).

67 lower risk of MACE (9.5% vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence interval: 0.68 to 0.8

68 lower risk for death or HF hospitalization (hazard ratio: 0.86; 95% confidence interval: 0.81 to 0.9

69 or HFH between 30 days and 2 years (adjusted hazard ratio: 0.91 per -5 mm Hg PASP; 95% confidence int

70 rgery group compared with the control group (hazard ratio=0.72 [95% CI, 0.57-0.92], P=0.008).

71 to not estimable) in the surgery only group (hazard ratio 1.01, 95% CI 0.71-1.44; log rank p=0.95).

72 failure than patients traveling <=60 miles (hazard ratio 1.09; 95% CI, 1.01-1.18), and a higher risk

73 gher risk of AF as a single factor (adjusted hazard ratio 1.11, 95% confidence interval 1.08-1.13).

74 9-1.67, p=0.76) and the rate (cause-specific hazard ratio 1.36, 95%CI 0.71-2.63, p=0.36) of the prima

75 e was associated with increased risk of AAA [hazard ratio 1.37 (1.14, 1.66)], but the association was

76 ose who had early-life material deprivation (hazard ratio 1.38, 95% CI 1.27-1.51), persistent depriva

77 s associated with a 1.6-fold increased risk (hazard ratio 1.58, 95% CI 1.08-2.31).

78 ated with greater risk of AAA in all models [hazard ratio 1.63 (1.24, 2.23)].

79 atal Tdap vaccination and ADHD in offspring (hazard ratio = 1.00, 95% confidence interval: 0.88, 1.14

80 d 12.5% for SAVR patients using claims data (hazard ratio, 1.02 [95% CI, 0.73-1.41]; P=0.58; interact

81 increments on CVD outcomes, including MI (MI hazard ratio, 1.07 per unit mm Hg increase in DBP; P<0.0

82 22; P = 0.67), and long-term graft survival (hazard ratio, 1.07; 95% CI, 0.86-1.33; P = 0.55).

83 ch was not significantly different (adjusted hazard ratio, 1.07; 95% confidence interval, 0.68-1.68;

84 or TAVR and 13.1% for SAVR using trial data (hazard ratio, 1.08 [95% CI, 0.79-1.48]; P=0.90), and 11.

85 significantly higher risk of death from NS (hazard ratio, 1.10 per year; P = .01).

86 th group 2 (11 [13.6%] versus 0%; P = 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.20

87 d after that time (week 15 through week 26) (hazard ratio, 1.13; 95% CI, 0.87 to 1.47).

88 admissions had shorter use (median, 0.84 d; hazard ratio, 1.22 [1.12-1.33]; P < 0.001).

89 roup and in 68 in the transvenous ICD group (hazard ratio, 1.23; 95% CI, 0.89 to 1.70); appropriate s

90 ated with increased incident CVD event risk (hazard ratio, 1.27 [95% CI, 1.04-1.56], P=0.019), with g

91 day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1.3; 95% CI, 0.8-2.2; P = .26).

92 ncidence of death or initiation of dialysis (hazard ratio, 1.48; 95% CI, 1.04 to 2.11; P = 0.03).

93 mpensations in patients with DACLD (adjusted hazard ratio, 1.4; 95% confidence interval: 0.9, 1.9; P

94 ccurred in 83 and 57 patients, respectively (hazard ratio, 1.52; 95% CI, 1.08 to 2.12).

95 associated with higher long-term mortality (hazard ratio, 1.57; 95% confidence interval, 1.25-1.99).

96 ), with greater risk from large CHIP clones (hazard ratio, 1.59 [95% CI, 1.21-2.09], P<0.001).

97 predictor of myocardial infarction (adjusted hazard ratio, 1.60 (95% CI, 1.10-2.34) per doubling; P=0

98 I versus the CABG group (44.5% versus 31.9%; hazard ratio, 1.60 [95% CI, 1.15-2.22]; P=0.005).

99 rom left ventricular ejection fraction, 50%; hazard ratio, 1.63 [95% CI, 1.30-2.04]; P<0.001) were in

100 d a higher risk for treated acute rejection (hazard ratio, 1.63; 95% CI, 1.43-1.86).

101 se in untreated HIV-positive women (adjusted hazard ratio, 1.63; 95% confidence interval, 1.59-1.67)

102 a history of >=2 HFHs in the past 12 months (hazard ratio, 1.77 [95% credible interval, 1.18-2.66], p

103 nconclusive tests (stress: 3.7% versus 2.0%, hazard ratio, 1.81, P=0.034; CTA: 5.0% versus 2.2%, haza

104 , compared with having no SDV, having 1 SDV (hazard ratio, 1.85 [95% CI, 1.12-3.05]), 2 SDVs (hazard

105 ratio, 1.81, P=0.034; CTA: 5.0% versus 2.2%, hazard ratio, 1.85; P=0.044) and positive tests (stress:

106 Male sex (hazard ratio, 1.89 [95% CI, 1.04-3.44]; P=0.04) and left

107 vessel myocardial infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08-3.40]; P=0.023) was low

108 The effect of reduced LV(EV) on mortality (hazard ratio: 1.07; 95% CI: 1.05, 1.09) did not vary by

109 n independent predictor of death/transplant (hazard ratio: 1.32; 95% confidence interval: 1.11 to 2.0

110 ith greater risk of subsequent MI or stroke (hazard ratio: 1.34; 95% confidence interval: 1.28 to 1.4

111 ) allele of CFH rs1329428 (P = 2.0 x 10(-3); hazard ratio: 1.74:95%CI: 1.16-2.59) after adjusting for

112 ignificantly associated with death (adjusted hazard ratio: 1.75; 95% CI: 1.37 to 2.24; p < 0.001) whi

113 e 2 MI was associated with higher all-cause (hazard ratio: 1.8; 95% confidence interval: 1.2 to 2.7;

114 zophrenia after substance-induced psychosis (hazard ratio=1.87, 95% CI=1.07- 3.26).

115 onarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96-40.95]).

116 dicted higher incidence of both neovascular (hazard ratio, 11.036; 95% confidence interval [CI], 1.80

117 e transplant-free survival during follow-up (hazard ratio, 11.21; P=1.61x10(-05)) than that of patien

118 KD, with the highest risk for heart failure (hazard ratio, 11.40; 95% confidence interval, 8.38 to 15

119 ence interval [CI], 1.807-67.393) and total (hazard ratio, 11.425, 95% CI, 1.940-67.300) events.

120 erapy was associated with tumor progression (hazard ratio, 18.7; P < .0001), formation of distant met

121 sease and 88.6% for femoropopliteal disease (hazard ratio 2.46, 99% CI 0.96 - 6.30, P = 0.013).

122 risk difference, 1.07%; 95% CI, 0.46%-1.69%; hazard ratio, 2.07; 95% CI, 1.48 to 2.88).

123 rd ratio, 1.85 [95% CI, 1.12-3.05]), 2 SDVs (hazard ratio, 2.12 [95% CI, 1.28-3.50]), and 3+ SDVs (ha

124 years than HCR patients (88.2% versus 76.6%; hazard ratio, 2.22 [1.44-3.42]).

125 Kidney dysfunction (hazard ratio, 2.28 [95% credible interval, 1.59-3.28], p

126 tio, 2.12 [95% CI, 1.28-3.50]), and 3+ SDVs (hazard ratio, 2.45 [95% CI, 1.48-4.04]) were significant

127 or probable stent thrombosis (5% versus 11%; hazard ratio, 2.52 [95% CI, 1.23-5.18]; P=0.009), and ta

128 On multivariable analysis, only multiple AP (hazard ratio, 2.78 [95% CI, 1.063-4.74]) and radiofreque

129 nts (36%), 2 of 11 (18%), and 5 of 12 (42%) (hazard ratios, 2.03 [95% CI, 0.43 to 9.62] and 0.84 [95%

130 isk) allele of ARMS2 A69S (P = 2.0 x 10(-4); hazard ratio: 2.18:95%CI: 1.47-3.24) and C(risk) allele

131 .7; p = 0.004) and cardiovascular mortality (hazard ratio: 2.7; 95% confidence interval: 1.4 to 5.1;

132 and shorter disease-specific survival times (hazard ratio, 23.1; P < .0001).

133 oth uni- and multivariate analysis (adjusted hazard ratio 3.05 and 1.88, respectively).

134 ndently associated with prophylaxis failure (hazard ratio, 3.39; P = .045) and infections with QR-GNB

135 dent predictor of appropriate ICD therapies (hazard ratio, 3.47 [95% CI, 1.19-10.11]), and its integr

136 nd positive tests (stress: 8.3% versus 2.0%, hazard ratio, 3.50; CTA: 9.2% versus 2.2%, hazard ratio,

137 uent with FFR-guided PCI (24.9% versus 8.2%; hazard ratio, 3.51 [95% CI, 1.93-6.40]; P<0.001).

138 , hazard ratio, 3.50; CTA: 9.2% versus 2.2%, hazard ratio, 3.66; P<0.001).

139 ell as those with low IL-6 treated with TCZ (hazard ratio, 3.6; P = .016).

140 ce of stroke than the conservative strategy (hazard ratio, 3.76; 95% CI, 1.52 to 9.32; P = 0.004) and

141 of a first hepatic decompensation (adjusted hazard ratio, 3.7; 95% confidence interval: 1.1, 12.6; P

142 ion was change in SUV(hetero) (PET1 to PET3; hazard ratio, 3.88; 95% CI, 1.24 to 12.1).

143 .2; P < .001) and those with DACLD (adjusted hazard ratio, 3.8; 95% confidence interval: 1.7, 9.5; P

144 subjects, and was associated with mortality (hazard ratio, 3.9; 95% CI, 1.09 to 14.14).

145 P < .0001), formation of distant metastases (hazard ratio, 32.1; P < .0001), and shorter disease-spec

146 ays; P < 0.001) and increased risk of death (hazard ratio = 4.1; P < 0.001).

147 iofrequency consolidation time < 90 seconds (hazard ratio, 4.38 [95% CI, 1.92-9.51]) remained signifi

148 not treated with TCZ showed high mortality (hazard ratio, 4.6; P = .003), as well as those with low

149 tality in both patients with CACLD (adjusted hazard ratio, 7.4; 95% confidence interval: 2.7, 20.2; P

150 amputation or peripheral revascularization (hazard ratio: 8.13; 95% confidence interval: 7.96 to 8.2

151 riate analysis, alemtuzumab (subdistribution hazard ratio, 9.0; 95% CI, 1.50-54.0; P = .02) was indep

152 of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 [95% CI, 1.23-68.92]; P=0.0085), the

153 notype, the effect of OSA showed an adjusted hazard ratio (95% confidence interval) of 1.54 (1.06-2.2

154 .351], P=0.007), and MACE risk (standardized hazard ratio [95% CI]: 1.927 [1.370-2.711], P=0.001).

155 ificantly associated with clinical outcomes (hazard ratio [95% confidence interval], 4.8 [2.6-9.0], P

156 cremental tertiles of time-varying total SB (hazard ratios [95% CI], 1.00 [referent], 1.15 [1.01-1.31

157 On multivariate regression (odds ratio or hazard ratio, 95% confidence interval), diabetes (1.9, 1

158 had a similar 1-year risk of death (adjusted hazard ratio [adjHR]: 0.92; 95% CI: 0.46 to 1.84) and hi

159 tion were associated with increased adjusted hazard ratio (aHR) for MACCE or all-cause mortality (aHR

160 onal propensity scores, to generate adjusted hazard ratios (aHR).

161 .5%) had a lower chance of listing (adjusted hazard ratio [aHR] = 0.68, 95% confidence interval [CI],

162 with a lower risk of CMV infection (adjusted hazard ratio [aHR]: 0.63; 95% confidence interval [CI],

163 hin the first month posttransplant (adjusted hazard ratio [aHR]: 2.493.494.89, P < 0.001), but a 62%

164 ompeting risks analysis to estimate adjusted hazard ratios (aHRs).

165 g to account for confounding when estimating hazard ratios and counterfactual risk functions.

166 d Cox regression models to calculate overall hazard ratios and time-dependent hazard ratios for pairs

167 ces in survival were markedly attenuated and hazard ratios approached 1.0.

168 odels for respective comparators resulted in hazard ratios below the null, except for vancomycin vs.

169 A in terms of biopsy-proven acute rejection (hazard ratio [confidence interval], 0.32 [0.11-0.90], P

170 The hazard ratio for 28-day mortality of diabetic patients,

171 The median hazard ratio for an association between a mental disorde

172 For FF/UMEC/VI, the hazard ratio for death was 0.72 (95% confidence interval

173 and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P =

174 r use (median, 1.35 d vs. 1.04 d for normal; hazard ratio for discontinuation vs. normal, 0.78 [0.73-

175 s [95% CI, 7.0 to 9.0 months], respectively; hazard ratio for disease progression or death, 0.51 [95%

176 ffect for female and male patients (adjusted hazard ratio for females: 0.90 [95% confidence interval:

177 In contrast, the adjusted hazard ratio for major amputations was 1.00 (95% CI, 0.9

178 confidence interval: 0.54 to 1.51]; adjusted hazard ratio for males: 0.76 [95% confidence interval: 0

179 increased risk for all-cause death (adjusted hazard ratio for moderate and severe degrees of malnutri

180 in the RA arm versus 83.7% in the RITA arm (hazard ratio for mortality, 0.53 [95% CI, 0.30-0.95]).

181 We estimated hazard ratios for all-cause mortality and deaths from ca

182 ds regression modeling was used to determine hazard ratios for coronary heart disease, CVD, and all-c

183 In multivariable analysis, the hazard ratios for CRC incidence after high-quality versu

184 Adjusted hazard ratios for DFS and OS were, respectively, 1.12 (9

185 The adjusted hazard ratios for high (vs.

186 Hazard ratios for mortality were calculated by using Cox

187 ate overall hazard ratios and time-dependent hazard ratios for pairs of mental disorders and medical

188 86.4%, p < 0.001) than those with NOM, with hazard ratio (HR) 0.72 (95%CI 0.57-0.91).

189 AR was associated with a lower rate of MACE [hazard ratio (HR) 0.87 (0.80-0.94)], and a lower rate of

190 t associated with tumor recurrence [adjusted hazard ratio (HR) 1.02, 95% confidence interval (CI) 0.8

191 lated death was associated with: being male (hazard ratio (HR) 1.59 (95% confidence interval 1.53-1.6

192 g-term mortality was higher following FEVAR [Hazard Ratio (HR) 1.7 (1.1-2.6), P = 0.02].

193 s, women attending less than once per month (hazard ratio (HR) = 0.97, 95% confidence interval (CI):

194 roportional hazards modeling to estimate the hazard ratio (HR) and 95% confidence interval (CI) for t

195 rtional hazards models were used to estimate hazard ratio (HR) and 95% confidence interval (CI).

196 Primary outcomes included hazard ratio (HR) and cumulative incidence for SCZ and B

197 The hazard ratio (HR) for febuxostat versus allopurinol in a

198 d model (Gradient Boosting-Colon) provided a hazard ratio (HR) for high- vs. low-risk recurrence of 8

199 The hazard ratio (HR) for the imputed aggregate treatment ef

200 nal hazards models were used to estimate the hazard ratio (HR) of risk factors associated with rehosp

201 also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square t

202 lower rates of long-term mortality (adjusted hazard ratio (HR), 0.473; 95% CI, 0.392-0.571; p < 0.001

203 longed with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P = .136]

204 lung primary was associated with longer DFS [hazard ratio (HR): 0.49, P = 0.008).

205 h risk factor, estimated all-cause mortality hazard ratios (HR) and population attributable fractions

206 0-82.7), respectively (low-risk vs high-risk hazard ratio [HR] 0.04, 95% CI 0.0-0.1, p<0.0001).

207 6.3 months (6.2-7.0) in group C (stratified hazard ratio [HR] 0.82, 95% CI 0.70-0.96; one-sided p=0.

208 SAF was an independent risk factor for CVEs (hazard ratio [HR] 1.12 per SD, 95% CI 1.03-1.22, p = 0.0

209 igher risk of death in univariable analysis (hazard ratio [HR] 2.13 [95% CI 1.49 to 3.02], P < 0.001)

210 4-0.34) with high-performing colonoscopists (hazard ratio [HR] 2.35; 95% CI 1.31-4.21; P = .004).

211 Male sex (hazard ratio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P

212 roke risk in TIA patients with positive DWI (hazard ratio [HR] = 0.54; 95% confidence interval [CI],

213 associated with twice the 5-year mortality (hazard ratio [HR] = 2.11; 95% confidence interval [CI]:

214 catheter-related VTE than subjects with TLs (hazard ratio [HR] = 8.5; 95% confidence interval [CI], 3

215 oximately 8.5 years to 6 months in the past (hazard ratio [HR] for <50 vs >=500 cells/uL, 13.4; 95% c

216 adjusted overall mortality decreased by 24% (hazard ratio [HR] per year 0.976; 95% confidence interva

217 ath was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P < .0001

218 start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .

219 se mortality (13 studies, n = 36 986; pooled hazard ratio [HR], 0.40 [95% CI, 0.28-0.56) and hepatoce

220 entile) was associated with better survival (hazard ratio [HR], 0.45; P = 0.024), whereas a (68)Ga-DO

221 7.76 at an SSF of 2 showed better 5-year OS (hazard ratio [HR], 0.53 [95% confidence interval {CI}: 0

222 t (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]).

223 al antiplatelet therapy (1.97% versus 3.13%; hazard ratio [HR], 0.60 [95% CI, 0.45-0.79]), with no in

224 s) independently correlates with longer PFS (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0

225 s 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59-0.80]; P=0.000001)

226 previous use of any hormonal contraceptives (hazard ratio [HR], 0.70; 95% CI, 0.68-0.72), combined (H

227 empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI, 0.67-0.87; P<0.0001).

228 On multivariable analysis, lung EHD (hazard ratio [HR], 0.7; 95% CI, 0.3-1.4), peritoneal EHD

229 nificantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cau

230 for age, sex, and medical history (adjusted hazard ratio [HR], 0.83 [95% CI, 0.67-1.03]).

231 not significantly reduce first HHF/CV death (hazard ratio [HR], 0.88 [95% CI, 0.75-1.03]).

232 rdial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95% CI, 0.80-1.06]) but were as

233 tiation with bevacizumab versus ranibizumab (hazard ratio [HR], 0.96 [95% confidence interval {CI}, 0

234 e incidence of the primary ischemic outcome (hazard ratio [HR], 0.97 [95% CI, 0.88-1.06]) was similar

235 dently associated with worse OS and DFS (OS: hazard ratio [HR], 0.98; confidence interval [CI], 0.97-

236 h a 0.9% increase in the risk of graft loss (hazard ratio [HR], 1.009; P < 0.001).

237 clinical risk factors or high genetic risk (hazard ratio [HR], 1.02; absolute risk reduction [ARR],

238 long-term (beyond 12 mo) CVE were age at LT (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1

239 = 1386 events; median follow-up, 25.2 years; hazard ratio [HR], 1.06 [95% CI, 0.89-1.26]), HF (n = 13

240 IOL was not predictive of nAMD development (hazard ratio [HR], 1.075; 95% confidence interval [CI],

241 , myocardial infarction, or stroke (adjusted hazard ratio [HR], 1.23 [95% CI, 0.97-1.56], P=0.094) an

242 icantly associated with all-cause mortality (hazard ratio [HR], 1.49 [CI, 1.15 to 1.94]) and cardiova

243 apnea associated with increased risk of CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI

244 ated with increased risk of macular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1

245 arly stage PDAC (13.5 months vs 23.3 months; hazard ratio [HR], 1.87; 95% confidence interval [CI]: 1

246 cantly increased the rate of immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1

247 An index visit with a nephrologist (hazard ratio [HR], 2.05 [95% CI, 1.66 to 2.52]) or an en

248 rtial or complete response rates (64% v 39%; hazard ratio [HR], 2.47; 95% CI, 1.30 to 4.71) and impro

249 .31) and associated with plaque positioning (hazard ratio [HR], 2.81 for no safety margin; P = 0.041)

250 32 versus 0.75 events per 100 patient-years (hazard ratio [HR], 3.05 [95% CI, 1.65 to 5.62]; P < 0.00

251 60 years at relapse had shorter second PFS (hazard ratio [HR], 3.0; P = .0029) and were mostly treat

252 genic/likely pathogenic sarcomeric variants (hazard ratio [HR], 5.6 [95% CI, 2.3-13.5]), atrial fibri

253 with a bleeding event had a 10.8% mortality (hazard ratio [HR], 5.97 [95% CI, 4.76-7.49]; P<0.001), a

254 ificantly associated with increased relapse (hazard ratio [HR], 6.38; 95% CI, 3.37 to 12.10; P < .001

255 ctive factor for graft and patient survival (hazard ratio [HR]: 0.67; P = .005, and HR: 0.65; P = .00

256 with both incident MACE and CV readmission (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0

257 verall survival benefit versus placebo drug (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0

258 anic patients had a higher rate of referral (hazard ratio [HR]: 1.22; 95% confidence interval [CI]: 1

259 n 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1

260 th 5-year cardiovascular mortality (adjusted hazard ratio [HR]: 2.18 [95% CI: 1.13 to 4.23] and 2.87

261 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% confidence interval [CI]: 2

262 Maternal age <20 years (hazard ratio [HR]: 2.40; 95% confidence interval (CI): 1

263 ubstantial for severe arrhythmia (univariate hazard ratio [HR]: 2.70; 95% confidence interval [CI]: 1

264 D1A mutation was associated with greater OS (hazard ratio [HR]: 3.1; 95% CI: 1.2, 10; P = .01).

265 Inactivity (hazard ratio [HR]: 6.59; 95% confidence interval [CI]: 3

266 th patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with

267 Adjusted hazard ratios (HRs) and 95% CIs were estimated in each d

268 Covariate-adjusted hazard ratios (HRs) and 95% CIs were estimated using Cox

269 Hazard ratios (HRs) and 95% confidence intervals (CIs) f

270 Hazard ratios (HRs) and receiver operating characteristi

271 We used hazard ratios (HRs) derived from Cox proportional hazard

272 Cox proportional hazard models estimated hazard ratios (HRs) for chronic health conditions and 95

273 atching time variable), was used to estimate hazard ratios (HRs) for lung cancer incidence by sex, to

274 Cox regression was used to estimate hazard ratios (HRs) for severe liver disease at 5, 10, a

275 Hazard ratios (HRs) for the effects of radiotherapy timi

276 ortality or in hospital discharge rate, with hazard ratios (HRs) of 1.03 (95% confidence interval [CI

277 Hazard ratios (HRs) of CVD < 1 year after initiation of

278 ednisolone-equivalent dose-related risks and hazard ratios (HRs) of first all-cause and type-specific

279 Compared with 2000 to 2004, the adjusted hazard ratios in 2013 to 2016 were 0.73 (95% CI, 0.62-0.

280 e viral load >=100'000 cps/mL (multivariable Hazard Ratio (mHR): 2.2, 95% CI: 1.3-3.6) and an AIDS de

281 notype, the effect of OSA showed an adjusted hazard ratio of 0.69 (0.46-1.04; P value = 0.08).Conclus

282 Culture positivity at day 3 conferred a hazard ratio of 2.8 for requiring TPK (P = .03) but was

283 both male and female handgun owners, with a hazard ratio of 7.82 for men (95% CI, 7.26 to 8.43) and

284 , a Cox proportional-hazard model revealed a hazard ratio of 9.5 (P < 0.005) for the two predicted gr

285 to 2.08) genetically, and with corresponding hazard ratios of 1.06 (95% CI: 1.05 to 1.08) and 1.06 (9

286 Cox regression was used to estimate hazard ratios of dementia by LC-SES scores in race-speci

287 horts, and estimated the incidence rates and hazard ratios of developing aortic aneurysm or dissectio

288 Hazard ratios per 5 BMI units, calculated using proporti

289 ated with 10-year CHD incidence in ARIC with hazard ratios per SD increment of 1.24 (95% CI, 1.15 to

290 nt data within the UK Biobank: the estimated hazard ratios per standard deviation were 1.10 (95% conf

291 milar risk of graft failure (subdistribution hazard ratio [sHR] 0.74; 95% confidence interval [CI], 0

292 Serum cystatin C (CysC; subdistribution hazard ratio [SHR], 1.58; 1.07-2.33), episodes of previo

293 The mortality hazard ratio was high at 6.01 (95% CI, 4.02-10.72) withi

294 The adjusted hazard ratio was highest in patients who underwent isola

295 The survival hazard ratio was presented by machine-learning algorithm

296 A noninferiority margin of 1.08 in terms of hazard ratio was prespecified for the upper boundary of

297 m as having any grade of emphysema (adjusted hazard ratios were 1.5, 1.7, 2.9, 5.3, and 9.7, respecti

298 ve quantified treatment effects by using the hazard ratio, which is difficult to interpret for a posi

299 atients in the enhanced standard care group (hazard ratio with Yoga-CaRe: 0.90; 95% confidence interv

300 a significant predictor to survival, and the hazard ratios with 95% CI were 1.09 (0.79-1.49) and 1.54